Canada: The EPCAT III randomized trial has found that an aspirin-only regimen was as effective and safe as rivaroxaban for ...

Regimens may drop the direct anticoagulants for some patients, based on EPCAT III ...

Aspirin after an initial short course of rivaroxaban has been shown to be safe and effective for the prevention of venous thromboembolism after total hip or total knee arthroplasty, but uncertainty ...

In the COMPASS trial of patients with stable coronary or peripheral artery disease (PAD), the combination of aspirin plus rivaroxaban, 2.5 mg twice daily, provided a larger absolute benefit on ...

A large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease (VHD) found that use of apixaban was associated with a lower rate of ischemic stroke or systemic ...

Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin ...

Results of a large-scale observational study show that among patients aged 65 or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly ...

BACKGROUND: Direct oral anticoagulants such as apixaban and rivaroxaban, have transformed the management of thromboembolic disorders. Randomized controlled trials were initiated in 2017 (COBRRA-VTE ...

In PAD patients with chronic kidney disease who’ve undergone revascularization, rivaroxaban (Xarelto; Bayer/Janssen) can safely reduce major CV and limb events, new findings from the VOYAGER PAD trial ...

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients ...

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients ...